Inogen, Inc.

NASDAQ:INGN

Medical - Devices

Healthcare
$5.57 +0.71%

+$0.05 today

Market cap
$144.83M
Beta
1.59
P/E (TTM)
-7.0
EPS (TTM)
-$0.91
52W Low $5.34High $9.13

Volume 0.19M

Average 0.33M

INGN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Inogen, Inc.NASDAQ: INGN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$3.59M, compared with -$1.08M a year earlier. Trailing-twelve-month EBITDA was -$5.23M.

Context

  • EBITDA amounted to 0.8% of revenue in FY2025, down 3.8 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$6.52M (-139.8%) for the fiscal year ending Dec 2026, a slowdown from the +82.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.59M-54.4% QoQ
Last fiscal yearDec 2025
-$2.72M+82.4% YoY
LTMMar 2026
-$5.23M+26.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-232.2%-29.8%+202.4 pp
1 year+82.4%-139.8%-222.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(2.72M) USD
Year-over-year change
+82.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How INGN compares with its peers on the latest reported figures

  • INGN's LTM Mar 2026 EBITDA of -$5.23M is the 2nd highest of the 11 companies compared; the peer median is -$55.67M.
  • Its year-over-year change of +26.2% is the 3rd highest of 11, against a peer median of -53.7%.
  • EBITDA amounts to 1.5% of revenue for INGN, versus a peer median of 63.6%.
INGN Competitors Peer median
EBITDA for INGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNWVSANUWAVE Health, Inc.LTM Mar 2026$22.67M +217.1%+59.4%51.1%
INGNInogen, Inc.LTM Mar 2026-$5.23M +26.2%—1.5%
SGHTSight Sciences, Inc.LTM Mar 2026-$31.68M +27.7%—39.8%
SIShoulder Innovations, Inc.LTM Mar 2026-$41.14M -191.1%—76.3%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$45.49M -75.7%——
NNOXNano-X Imaging Ltd.LTM Dec 2025-$49M -11.0%—376.3%
OMOutset Medical, Inc.LTM Mar 2026-$62.35M +22.0%—53.0%
QTRXQuanterix CorporationLTM Mar 2026-$84.67M -104.0%—58.4%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$110.64M -31.7%—17902.8%
HSDTSolana CompanyLTM Mar 2026-$135.55M -1012.4%—1413.6%
HCATHealth Catalyst, Inc.LTM Mar 2026-$192.37M -1267.9%—63.6%
Peer median (excluding INGN) -$55.67M-53.7%+59.4%63.6%

Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue358M377.24M315.66M335.71M348.67M
Cost of Revenue181.52M223.71M188.96M180.96M182.78M
Gross Profit176.48M153.53M126.7M154.74M165.89M
Gross Margin49.3%40.7%40.1%46.1%47.6%
Research & Development16.58M21.94M20.84M21.61M19.4M
Selling, General & Admin150.67M164.67M182.35M175.65M165.07M
Operating Expenses167.24M238.78M236.09M197.26M196.1M
Depreciation & Amortization21.63M23.51M18.15M21M20.66M
EBITDA30.29M(9.57M)(58.34M)(15.47M)(2.72M)
EBITDA Margin8.5%-2.5%-18.5%-4.6%-0.8%
Operating Income9.24M(85.24M)(109.39M)(42.52M)(30.21M)
Operating Margin2.6%-22.6%-34.7%-12.7%-8.7%
Interest Income129K2.84M6.57M5.19M2.15M
Interest Expense00000
Other Income / Expenses(581K)1.98M7.04M6.04M6.83M
Income Before Tax8.66M(83.27M)(102.34M)(36.48M)(23.38M)
Pre-Tax Margin2.4%-22.1%-32.4%-10.9%-6.7%
Income Tax Expense14.99M504K105K(588K)(632K)
Net Income(6.33M)(83.77M)(102.45M)(35.89M)(22.75M)
Net Margin-1.8%-22.2%-32.5%-10.7%-6.5%
EPS (Basic)(0.28)(3.67)(4.42)(1.52)(0.85)
EPS (Diluted)(0.28)(3.67)(4.42)(1.52)(0.85)
Weighted Avg Shares22.49M22.85M23.18M23.65M27.18M
Weighted Avg Shares (Diluted)22.49M22.85M23.18M23.65M27.18M

Inogen, Inc.

NASDAQ:INGN

Intrinsic Alpha fair value

Locked

Current Price

$5.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.